| Literature DB >> 30193095 |
Anne Ast1, Alexander Buntru1, Franziska Schindler1, Regine Hasenkopf1, Aline Schulz1, Lydia Brusendorf1, Konrad Klockmeier1, Gerlinde Grelle1, Benjamin McMahon1, Hannah Niederlechner1, Isabelle Jansen1, Lisa Diez1, Juliane Edel1, Annett Boeddrich1, Sophie A Franklin2, Barbara Baldo3, Sigrid Schnoegl1, Severine Kunz4, Bettina Purfürst4, Annette Gaertner5, Harm H Kampinga6, A Jennifer Morton7, Åsa Petersén3, Janine Kirstein8, Gillian P Bates2, Erich E Wanker9.
Abstract
Self-propagating, amyloidogenic mutant huntingtin (mHTT) aggregates may drive progression of Huntington's disease (HD). Here, we report the development of a FRET-based mHTT aggregate seeding (FRASE) assay that enables the quantification of mHTT seeding activity (HSA) in complex biosamples from HD patients and disease models. Application of the FRASE assay revealed HSA in brain homogenates of presymptomatic HD transgenic and knockin mice and its progressive increase with phenotypic changes, suggesting that HSA quantitatively tracks disease progression. Biochemical investigations of mouse brain homogenates demonstrated that small, rather than large, mHTT structures are responsible for the HSA measured in FRASE assays. Finally, we assessed the neurotoxicity of mHTT seeds in an inducible Drosophila model transgenic for HTTex1. We found a strong correlation between the HSA measured in adult neurons and the increased mortality of transgenic HD flies, indicating that FRASE assays detect disease-relevant, neurotoxic, mHTT structures with severe phenotypic consequences in vivo.Entities:
Keywords: Drosophila; FRASE assay; HSA; Huntington’s disease; disease marker; huntingtin; mutant HTT seeding; proteotoxicity; seeding activity; self-propagation
Mesh:
Substances:
Year: 2018 PMID: 30193095 DOI: 10.1016/j.molcel.2018.07.032
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970